Radioprotectants: Current status and new directions

Oncology

Volumn 63, Issue SUPPL. 2, 2002, Pages 2-10

  Grdina, David J ^a,b   Murley, Jeffrey S ^a   Kataoka, Yasushi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Amifostine; Cytoprotection; Mutagenesis; Radiation induced toxicity; Radiotherapy; Thiol compounds

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACETYLCYSTEINE; AMIFOSTINE; ANTIOXIDANT; CAPTOPRIL; DRUG METABOLITE; MANGANESE SUPEROXIDE DISMUTASE; MESNA; MITOCHONDRIAL ENZYME; RADIOPROTECTIVE AGENT; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; THIOL DERIVATIVE; WR 332728;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CELL DEATH; CELL PROTECTION; CHEMOTHERAPY; DNA DAMAGE; DOSE RESPONSE; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IRRADIATION; MUTAGENESIS; PRIORITY JOURNAL; RADIATION PROTECTION; REVIEW; TISSUE INJURY; XEROSTOMIA;

ACROLEIN; AMIFOSTINE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEART; HUMANS; MESNA; MUTAGENESIS; OXAZINES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RAZOXANE;

EID: 0036916372     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067146     Document Type: Review

References (26)

1. Curran WJ: Radiation-induced toxicities: The role of radioprotectants. Semin Radiat Oncol 1998;8(4 suppl 1):2-4.
2. Brizel DM: Future directions in toxicity prevention. Semin Radiat Oncol 1998;8(4 suppl 1):17-20.
3. Schuchter LM: Current role of protective agents in cancer treatment. Oncology (Huntingt) 1997;11:505-512, 515-518.
4. Hoekman K, van der Vijgh WJF, Vermorken JB: Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 1999;57:133-155.
5. Links M, Lewis C: Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308.
6. Culy CR, Spencer CM: Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;61:641-684.
7. Schuchter LM: Guidelines for the administration of amifostine. Semin Oncol 1996;23(4 suppl 8):40-43.
8. 2. Ann Oncol 2000;11:1029-1033.
9. Wiseman LR, Spencer CM: Dexrazoxane: A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998;56:385-403.
10. Hasinoff BB: The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Agents Actions 1990;29:374-381.
11. Koning J, Palmer P, Franks CR, Mulder DE, Speyer JL, Green MD, Hellmann K: Cardioxane - ICRF-187 towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 1991;18:1-19.
12. Hall EJ: Radiobiology for the Radiologist, Ed 5. Philadelphia, Lippincott Williams & Wilkins, 2000.
13. Zheng S, Newton GL, Gonick G, Fahey RC, Ward JF: Radioprotection of DNA by thiols: Relationship between the net charge on a thiol and its ability to protect DNA. Radiat Res 1988;114:11-27.
14. Zheng S, Newton GL, Ward JF, Fahey RC: Aerobic radioprotection of pBR322 by thiols: Effect of thiol net charge upon scavenging of hydroxyl radicals and repair of DNA radicals. Radiat Res 1992;130:183-193.
15. Grdina DJ, Nagy B, Hill CK, Wells RL, Peraino C: The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 1985;6:929-931.
16. Grdina DJ, Shigematsu N, Dale P, Newton GL, Aguilera JA, Fahey RC: Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995;16:767-774.
17. Shaw LM, Bonner HS, Schuchter L, Schiller J, Lieberman R: Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 1999;26(2 suppl 7):34-36.
18. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18: 3339-3345.
19. Epperly MW, Gretton JA, DeFilippi SJ, Greenberger JS, Sikora CA, Liggitt D, Koe G: Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. Radiat Res 2001;155:2-14.
20. Epperly MW, Kagan VE, Sikora CA, Gretton JE, Defilippi SJ, Bar-Sagi D, Greenberger JS: Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. Int J Cancer 2001;96:221-231.
21. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ: Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med 2001;30:1426-1439.
22. Das KC, Lewis-Molock Y, White CW: Activation of NF-kappa B and elevation of MnSOD gene expression by thiol-reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol 1995;269(5 Pt 1):L588-L602.
23. Antras-Ferry J, Maheo K, Chevanne M, Dubos MP, Morel F, Guillouzo A, Cillard P, Cillard J: Oltipraz stimulates the transcription of the manganese superoxide dismutase gene in rat hepatocytes. Carcinogenesis 1997;18:2113-2117.
24. List AF: Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin Oncol 1999;26(2 suppl 7):61-65.
25. Jongen-Lavrencic M, Peeters HR, Vreugdenhil G, Swaak AJ: Interaction of inflammatory cytokines and erythropoietin in iron metabolism and erythropoiesis in anaemia of chronic disease. Clin Rheumatol 1995;14:519-525.
26. Zhu J, Heyworth CM, Glasow A, Huang QH, Petrie K, Lanotte M, Benoit G, Gallagher R, Waxman S, Enver T, Zelent A: Lineage restriction of the RARalpha gene expression in myeloid differentiation. Blood 2001;98:2563-2567.